Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus gemcitabine versus placebo plus gemcitabine in second-line advanced malignant pleural mesothelioma
2016-001132-36Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma comparing Ramucirumab + gemcitabine with Placebo + gemcitabine (2 arms). Primary endpoint: Overall survival. Started Feb 2021; status: completed.
02
Drugs
ramucirumabgemcitabine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2016-001132-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001132-36.